Non-cell Corynebacterium parvum generated by nanotechnology:: A promising immunomodulator with less side effects

被引:21
作者
Gao, Shangxian
Liu, Chenghu
Qu, Shoufang
Song, Jing
Li, Jianfeng
Zhang, Pin
Wang, Qun
Guo, Chun
Gao, Fei
Zhang, Lining
机构
[1] Shandong Univ, Sch Med, Inst Immunol, Jinan 250012, Peoples R China
[2] Natl Inst Control Pharmaceut & Biol Prod, Dept Medium, Beijing, Peoples R China
[3] Shandong Prov Hosp, Cent Lab, Jinan 250021, Shandong, Peoples R China
基金
中国国家自然科学基金;
关键词
Corynebacterium parvum; tumor; immunomodulator; macrophage;
D O I
10.1016/j.intimp.2007.05.018
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 [免疫学];
摘要
Corynebacterium parvum (CP), a kind of immunomodulator, has been well documented in immunotherapy to tumor. However, severe side effects, such as intrahepatic granulomas and scleromes in injected areas, restrict its clinical application. To minimize side effects of CP, a non-cell Corynebacterium parvum product (NCPP) was prepared by disposing CP with Nanotechnology. In present study, we compared effect of NCPP with that of CP and found: (1) NCPP with non-formaldehyde residue was easy to be absorbed without swelling and sclerome in local injected areas; (2) NCPP caused no obvious liver injury in murine and macaques; (3) NCPP maintained powerful anti-tumor activity, increased splenic index, elevated macrophage number, phagocytosis and production of hydrogen peroxide (H2O2), and nitric oxide (NO); (4) Importantly, unparallel CP, NCPP could stimulate macrophages to produce low level of tumor necrosis factor-alpha(TNF-alpha) but high level of interferon-gamma (IFN-gamma), an inhibitor to fibrosis. Our study has led to the view that NCPP will evolve into a new valuable immunomodulator for clinical application. (c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:1334 / 1342
页数:9
相关论文
共 39 条
[1]
Adlam C, 1977, Dev Biol Stand, V38, P115
[2]
ALABA O, 1980, J IMMUNOL, V124, P2688
[3]
ANANIAS RZ, 2001, SCAND J IMMUNOL S1, V54, P133
[4]
CASALI A, 1988, CANCER, V62, P806, DOI 10.1002/1097-0142(19880815)62:4<806::AID-CNCR2820620428>3.0.CO
[5]
2-4
[6]
Nanomedicine: An unresolved regulatory issue [J].
Chan, Vivian S. W. .
REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2006, 46 (03) :218-224
[7]
Chare M J, 1977, Dev Biol Stand, V38, P195
[8]
DING AH, 1988, J IMMUNOL, V141, P2407
[9]
THE ANTI-TUMOR ACTIVITY OF MALTOSE TETRAPALMITATE COMPARED WITH OTHER IMMUNOADJUVANTS, AND ITS EFFECTIVENESS AFTER TUMOR SURGERY [J].
ELKAPPANY, H ;
CHOPRA, C ;
NIGAM, VN ;
BRAILOVSKY, CA ;
ELHILALI, M .
BRITISH JOURNAL OF CANCER, 1980, 42 (05) :703-711
[10]
FISHER B, 1975, CANCER, V35, P134, DOI 10.1002/1097-0142(197501)35:1<134::AID-CNCR2820350119>3.0.CO